These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry. Frogel M; Nerwen C; Boron M; Cohen A; VanVeldhuisen P; Harrington M; Groothuis J; Pediatr Infect Dis J; 2008 Oct; 27(10):870-3. PubMed ID: 18776822 [TBL] [Abstract][Full Text] [Related]
6. Timing of monoclonal antibody for seasonal RSV prophylaxis in the United Kingdom. Goddard NL; Cooke MC; Gupta RK; Nguyen-Van-Tam JS Epidemiol Infect; 2007 Jan; 135(1):159-62. PubMed ID: 16753078 [TBL] [Abstract][Full Text] [Related]
7. [Chemoprophylaxis with palivizumab in Andalusia (Spain). Results of the 2000-2001 respiratory syncytial virus epidemic]. Grupo de Hospitales Benazuza An Esp Pediatr; 2002 Apr; 56(4):293-7. PubMed ID: 11927095 [TBL] [Abstract][Full Text] [Related]
8. Advances in the treatment and prevention of severe viral bronchiolitis. Domachowske JB; Rosenberg HF Pediatr Ann; 2005 Jan; 34(1):35-41. PubMed ID: 15693214 [TBL] [Abstract][Full Text] [Related]
9. Risk of severe respiratory syncytial virus disease, identification of high risk infants and recommendations for prophylaxis with palivizumab. Meissner HC; Rennels MB; Pickering LK; Hall CB Pediatr Infect Dis J; 2004 Mar; 23(3):284-5. PubMed ID: 15014320 [No Abstract] [Full Text] [Related]
10. Safety and tolerance of palivizumab administration in a large Northern Hemisphere trial. Northern Hemisphere Expanded Access Study Group. Groothuis JR Pediatr Infect Dis J; 2001 Jun; 20(6):628-30. PubMed ID: 11419509 [TBL] [Abstract][Full Text] [Related]
11. Development of a potent respiratory syncytial virus-specific monoclonal antibody for the prevention of serious lower respiratory tract disease in infants. Young J Respir Med; 2002 Apr; 96 Suppl B():S31-5. PubMed ID: 11996402 [No Abstract] [Full Text] [Related]
13. Safety and immunogenicity of palivizumab (Synagis) administered for two seasons. Null D; Pollara B; Dennehy PH; Steichen J; Sánchez PJ; Givner LB; Carlin D; Landry B; Top FH; Connor E Pediatr Infect Dis J; 2005 Nov; 24(11):1021-3. PubMed ID: 16282947 [TBL] [Abstract][Full Text] [Related]
14. Admission to the intensive care unit for respiratory syncytial virus bronchiolitis: a national survey before palivizumab use. Prais D; Schonfeld T; Amir J; Pediatrics; 2003 Sep; 112(3 Pt 1):548-52. PubMed ID: 12949282 [TBL] [Abstract][Full Text] [Related]
17. Long term follow-up of Palivizumab administration in children born at 29-32 weeks of gestation. Bar-Yoseph R; Haddad J; Hanna M; Kessel I; Kugelman A; Hakim F; Bentur L Respir Med; 2019 Apr; 150():149-153. PubMed ID: 30961942 [TBL] [Abstract][Full Text] [Related]
18. The association between respiratory syncytial virus infection and reactive airway disease. Piedimonte G Respir Med; 2002 Apr; 96 Suppl B():S25-9. PubMed ID: 11996401 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications. Hampp C; Kauf TL; Saidi AS; Winterstein AG Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647 [TBL] [Abstract][Full Text] [Related]
20. Prevention of respiratory syncytial virus infection in infants. Handforth J; Sharland M; Friedland JS BMJ; 2004 May; 328(7447):1026-7. PubMed ID: 15117767 [No Abstract] [Full Text] [Related] [Next] [New Search]